Oxiracetam

Overview

Oxiracetam is a non-peptide racetam-class cognitive enhancer, structurally the 4-hydroxy analog of piracetam. It is approved as a prescription drug for dementia in Italy (since 1984) and China, but is NOT FDA-approved in the United States. The FDA has classified oxiracetam as a 'new drug' requiring approval and determined it does not qualify as a dietary supplement; in the US it is sold only as an unregulated gray-market research chemical.

Mechanism of Action

Proposed mechanism (not fully established in humans) is positive modulation of AMPA-type glutamate receptors: in rat cortical synaptic membranes and cultured neurons, oxiracetam enhanced AMPA-stimulated calcium influx and modulated AMPA binding without affecting kainate or NMDA signaling. Separate preclinical work found oxiracetam increases depolarization-evoked acetylcholine, glutamate, and aspartate release from rat hippocampal slices (not synaptosomes), with in vivo microdialysis showing ~63% increase in hippocampal acetylcholine release at 100 mg/kg in rats. No human receptor-occupancy or mechanistic imaging data were found.

Research Summary

Multiple placebo-controlled human trials exist in dementia, organic brain syndrome, and traumatic brain injury populations, plus human pharmacokinetic studies. One double-blind controlled trial in elderly organic-brain-syndrome patients used doses titrated from 400–2400 mg/day; a separate placebo-controlled trial in senile dementia of Alzheimer type and multi-infarct dementia used 800 mg twice daily and reported improvement on cognitive measures versus placebo. Preclinical findings include AMPA receptor modulation and enhanced neurotransmitter release in rat hippocampal preparations, and identification of the (S)-enantiomer as the active component alleviating cognitive impairment in a rat chronic cerebral hypoperfusion model. Oral bioavailability in humans is ~56% (versus 28–42% in rats, 81–90% in dogs), with predominantly renal excretion of unchanged drug.

Reported Side Effects

• Reduced clearance in elderly and renally impaired patients (AUC doubled)
• Product identity/purity risk in gray-market sources (oxiracetam claimed but not detected in tested supplements)
• No FDA-approved safety profile; trial doses not general safety guidance
• Renal function materially affects drug elimination
• Unknown long-term safety profile in healthy populations

Compare Oxiracetam with Others

Research References

• Oxiracetam, PubChem Compound Summary for CID 4626 (identity independently verified via PUG REST API).
• Excitatory amino acids and neuronal plasticity: modulation of AMPA receptors as a novel substrate for the action of nootropic drugs (Nicoletti F, Casabona G, Genazzani AA, Copani A, et al.), Functional Neurology 1992. 1992. PMID 1338053.
• Effects of oxiracetam on neurotransmitter release from rat hippocampus slices and synaptosomes. PMID 1361044.
• Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus (Giovannini et al.), Drug Development Research 1993. 1993.

Frequently asked questions

Has Oxiracetam been independently lab-tested?

Disclosed Labs has collected 2 Certificates of Analysis (COA) for Oxiracetam from 2 independent testing labs. 1 vendor has submitted material for testing. Products average 99.4% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/oxiracetam/testing.

How does Oxiracetam work?

Proposed mechanism (not fully established in humans) is positive modulation of AMPA-type glutamate receptors: in rat cortical synaptic membranes and cultured neurons, oxiracetam enhanced AMPA-stimulated calcium influx and modulated AMPA binding without affecting kainate or NMDA signaling. Separate preclinical work found oxiracetam increases depolarization-evoked acetylcholine, glutamate, and aspartate release from rat hippocampal slices (not synaptosomes), with in vivo microdialysis showing ~63% increase in hippocampal acetylcholine release at 100 mg/kg in rats. No human receptor-occupancy or mechanistic imaging data were found.

What does the research say about Oxiracetam?

Multiple placebo-controlled human trials exist in dementia, organic brain syndrome, and traumatic brain injury populations, plus human pharmacokinetic studies. One double-blind controlled trial in elderly organic-brain-syndrome patients used doses titrated from 400–2400 mg/day; a separate placebo-controlled trial in senile dementia of Alzheimer type and multi-infarct dementia used 800 mg twice daily and reported improvement on cognitive measures versus placebo. Preclinical findings include AMPA receptor modulation and enhanced neurotransmitter release in rat hippocampal preparations, and identification of the (S)-enantiomer as the active component alleviating cognitive impairment in a rat chronic cerebral hypoperfusion model. Oral bioavailability in humans is ~56% (versus 28–42% in rats, 81–90% in dogs), with predominantly renal excretion of unchanged drug.